CKMT2

Across TCGA pan-cancer cohorts, CKMT2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CKMT2 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CKMT2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CKMT2 expression acts as an unfavorable survival marker, although some lineages such as OV and PDAC show a favorable association.

OV, PDAC, and HNSC are the cancer types where CKMT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Tertile	All	1.000	0.670	.025	4	view →
PDAC	DFS	Quartile	III,IV	0.458	0.151	.047	3	view →
HNSC	DFS	Tertile	III,IV	1.000	0.911	.042	2	view →
LSCC	DFS	Quartile	All	1.000	0.810	.040	1	view →
CCRCC	DFS	Median	II,III,IV	0.732	0.481	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CKMT2–OV (DFS)

Open the OV breakdown →